Compare DPRO & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DPRO | VYGR |
|---|---|---|
| Founded | 1998 | 2013 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 230.7M | 194.0M |
| IPO Year | 2019 | 2015 |
| Metric | DPRO | VYGR |
|---|---|---|
| Price | $6.90 | $4.14 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $15.67 | ★ $17.00 |
| AVG Volume (30 Days) | ★ 1.6M | 497.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,135,000.00 |
| Revenue This Year | $42.16 | N/A |
| Revenue Next Year | $145.52 | $71.77 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.63 | $2.65 |
| 52 Week High | $14.37 | $5.55 |
| Indicator | DPRO | VYGR |
|---|---|---|
| Relative Strength Index (RSI) | 43.90 | 60.10 |
| Support Level | $6.28 | $3.73 |
| Resistance Level | $7.15 | $4.44 |
| Average True Range (ATR) | 0.60 | 0.24 |
| MACD | -0.04 | 0.08 |
| Stochastic Oscillator | 19.08 | 81.19 |
Draganfly Inc is a Canada based company. It is engaged in the provision of engineering services and the manufacture of commercial unmanned vehicle systems and software. The company operates in Canada, the United States, and Internationally. The three segments are Drones, Vital (Vital Intelligence), and Corporate. The Drones segment derives its revenue from products and services related to the sale of unmanned aerial vehicles (UAV). The Vital segment derives its revenue from the sale of products that measure vitals to help detect symptoms from large groups of people from a distance. The Corporate segment includes all costs not directly associated with the Drone and Vital segments. It generates majority of its revenue from Drones segment.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.